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Abstract 
INTRODUCTION 
Prostate adenocarcinoma (PCa) is the second most frequent male neoplasm 
worldwide.[1] Metastatic spread frequently affects bone, lung, and liver. However, 
testicular metastases represented solely 0.5% of PCa metastases in an autopsy study 
of 1589 patients, and none was located in the epididymis.[2] The first report of 
epididymal metastasis from PCa dates from 1944, and the majority of cases 
diagnosed ever since were incidentally found during surgical castration.[3,4,5] We 
conducted a MEDLINE search, and only 26 cases have been reported worldwide. 
Herein, we report a case of this rare route of PCa dissemination, focusing on its 
diagnostic challenges and pitfalls. 
CASE REPORT 
A 69-year-old Caucasian man, with a medical history of colorectal adenocarcinoma 
at the age 37 years, was subject to radical prostatectomy and adjuvant radiation 
therapy at the age 63 years due to PCa, pT3N0M0R1-Gleason score 8 (5 + 3). Other 
comorbidities included high blood pressure and radiation-induced proctitis. 
Five years after treatment for PCa, biochemical recurrence was depicted. Bone-scan 
and abdominopelvic computed tomography did not disclose any metastatic lesion or 
local recurrence. As serum prostate-specific antigen (PSA) continued to rise, 
reaching 20 ng/mL, gallium-68 prostate-specific membrane antigen-positron 
emission tomography/computed tomography (68 Ga-PSMA PET/CT) was performed, 
showing high uptake in the left testis and retrovesical space [Figure 1]. A firm 
elastic nodularity with 2 cm was then found on clinical examination of the left 
epididymis, but the patient referred that it was an old lesion. Pelvic magnetic 
resonance confirmed the presence of a 2.2 cm solid, heterogeneous nodule, 
hypointense in T2 sequence, with arterial vascularization [Figure 2]. Due to the 
uncertainty about the neoplastic or inflammatory origin of the nodule, left radical 
orchiectomy was performed. 
Macroscopic examination of the surgical specimen revealed a 1.8 cm × 1.4 cm solid, 
rubbery, whitish nodule in the epididymal tail. The lesion was confined to the 
epididymis, sparing the testicular parenchyma [Figure 3a]. On histological 
examination, the lesion was composed of malignant glands infiltrating around the 
epididymal ducts [Figure 3b] as well as the adipose tissue/neurovascular structures 
[Figure 3c]. Immunohistochemical staining for PSA demonstrated strong diffuse 
cytoplasmic immunoreactivity in the neoplastic glands [Figure 3d]. 
Postoperative PSA was 62.70 ng/mL and palliative androgen deprivation therapy 
was started. The patient remains asymptomatic 4 months after surgery. 
DISCUSSION 
Epididymal masses are, overall, rare findings. Differential diagnosis includes both 
neoplastic (primary and metastatic) and nonneoplastic lesions. Benign tumors (such 
as lipomas and adenomatoid tumors) and several tumor-like lesions (including 
epididymal cysts and epididymitis) may truly simulate malignancies; thus, clinical 
awareness of these entities is fundamental. Concerning primary malignant tumors, 
sarcomas are among the most frequently arising in the paratesticular area.[6] 
Further, testicular tumors may show extension into paratesticular structures such as 
epididymis, which has implications on staging. Classical criteria used for favoring a 
metastatic tumor over a testicular primary include age >50 years, bilaterality, prior 
history of neoplasia, an infrequent morphology for a primary testicular/paratesticular 
tumor, lymphovascular invasion, and an intertubular growth pattern; all criteria were 
met in our patient, except bilateral involvement. In addition, immunohistochemical 
studies might be valuable in difficult cases, as proved to be in the current case, 
where the strong and diffuse cytoplasmic immunoreactivity of the tumor cells for 
PSA proved the prostatic origin. 
Metastatic tumors to the epididymis are exceedingly rare and have been reported to 
originate not only from the colon[7] and prostate[8] (the patient's previous 
neoplasms) but also from the kidney and bile ducts.[9] In a patient with a medical 
history of both colorectal and PCas, a metastatic origin for the epididymal mass 
should also be suspected and adequate clinical evaluation performed. 
There are few previous reports of PCa metastases to the epididymis. Most cases 
were asymptomatic and incidentally discovered at autopsy or after bilateral 
orchiectomy for castration purposes. Regarding dissemination routes, arterial 
embolization, retrograde venous extension, lymphatic extension, or retrograde 
intraluminal spread through the vas deferens have been proposed. In our case, as in 
other reports, the latter mechanism seems less likely as no intraluminal invasion was 
depicted, with tumor cells externally infiltrating around the epididymal ducts.[3] 
The diagnosis of biochemical failure is quite a challenge to urologists and 
oncologists, and many imaging methods of detecting it have been proposed.68 Ga-
PSMA PET/CT uses PSMA, a membrane-bound enzyme that has significantly 
elevated expression in prostate cancer cells, compared to benign prostatic tissue, and 
is one of the most recent advances in this field. Its value relies on the higher 
detection rates for recurrent disease when compared to other imaging modalities, 
even for patients with PSA values as low as 0.5 ng/mL.[10] In our case, in 
particular, this technique was crucial for the diagnosis of the epididymal metastasis 
as all the previous examinations were nondiagnostic. Prospective trials and clinical 
guidelines for this new technique are still missing; however,68 Ga-PSMA PET/CT 
could help identifying oligometastatic disease or local recurrence in patients with 
low PSA values and thus have impact on PCa management. 
Due to its rarity, the prognostic impact of this kind of metastasis is not known, thus 
precluding definitive statements regarding the most adequate therapeutic 
strategy.[4,5] Nevertheless, the case presented herein emphasizes the need for 
accurate diagnosis, which may require orchiectomy. Importantly, new imaging 
modalities, such as 68Ga-PSMA PET/CT, may improve patients' follow-up by 
increasing the accuracy of identification of metastatic lesions or local recurrence, 
allowing for timely therapeutic decision. 
CONCLUSION 
Despite constituting rare events, metastatic tumors should be considered in the 
differential diagnosis of epididymal masses, especially in older patients with a 
medical history of neoplasia. An accurate diagnosis is fundamental since it has 
implications both on prognosis and on therapeutic management and requires a good 
clinical, analytical, and pathological correlation since the disease can be quite silent. 
Only by being aware of this clinical scenario, can clinicians clinch this diagnosis and 
timely intervene to improve their patients' quality of life and survival. 
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Figures and Tables 
Figure 1 
 Gallium-68 prostate-specific membrane antigen-positron emission tomography/computed 
tomography clearly showing tracer uptake in the left testis, in correlation with the pathological 
findings 
Figure 2 
 Pelvic magnetic resonance on sagittal view confirming the presence of a 2.2 cm nodule 
circumscribed to the left epididymis, hypointense in T2 sequence 
Figure 3 
 Histopathological examination of the radical left orchiectomy specimen. (a) Macroscopy: 
Nodule in epididymal tail (arrow). (b and c) Histology (H and E, ×100): Epididymal metastasis 
infiltrating epididymal ducts (b) and neurovascular structures (c). (d) Immunohistochemistry 
(PSA, ×200): Diffuse cytoplasmic immunoreactivity 
 
